Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
A major impediment to the use of adeno-associated virus (AAV)-mediated gene delivery to muscle in clinical applications is the pre-existing immune responses against the vector. Pre-existing humoral response to different AAV serotypes is now well documented. In contrast, cellular responses to AAV capsid have not been analyzed in a systematic manner, despite the risk of T cell reactivation upon gene transfer. AAV1 has been widely used in humans to target muscle. In this study, we analyzed PBMCs and sera of healthy donors for the presence of AAV1 capsid-specific T cell responses and AAV1 neutralizing factors. Approximately 30% of donors presented AAV1 capsid-specific T cells, mainly effector memory CD8+ cells. IFN-γ–producing cells were also observed among effector memory CD4+ cells for two of these donors. Moreover, to our knowledge, this study shows for the first time on a large cohort that there was no correlation between AAV1-specific T cell and humoral responses. Indeed, most donors presenting specific Ig and neutralizing factors were negative for cellular response (and vice versa). These new data raise the question of prescreening patients not only for the humoral response, but also for the cellular response. Clearly, a better understanding of the natural immunology of AAV serotypes will allow us to improve AAV gene therapy and make it an efficient treatment for genetic disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies characterized T-cell responses in healthy human subjects and reported 10–100% of human subjects have functional circulating capsid-specific T cells against multiple AAV serotypes [109–111].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [110]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“Furthermore, it has been shown that the host immune response to the AAV capsid mediated by circulating Abs may prevent repeated administrations (9).”
BackgroundXiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“Briefly, HEK293 cells were tritransfected with the adenovirus helper plasmid pXX6 (22), a pAAV packaging plasmid expressing the rep and cap genes pLT-RC02 for AAV1 (23) and the relevant pAAV2 vector plasmid.”
MethodClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 2×
“80% homology at the nucleotide level, suggesting cross-reactions between them (18).”
BackgroundKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 12×
“Briefly, CD3, CD4, CD8, CD45RA, CD62L, and CD25 Abs were diluted in PBS with 3% FCS at recommended concentrations and were added to the cells for 30 min at 4˚C in the dark.”
BackgroundMethodResultSelf-citationWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 2×
“(8), which was consistent with another report concerning Europe (7).”
ResultAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 17×
“The frequency of circulating capsid-specific T cells was determined by IFN-g ELISPOT in which cells were stimulated with AAV-specific overlapping peptides (12, 16).”
BackgroundMethodInfluentialMoss, R. B., Rodman, D., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D., Milla, C., Brody, A. S., Clancy, J. P., Ramsey, B., et al. (2004) · Chest · doi:10.1378/chest.125.2.509 · Cited by 390
Flotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335
Research works printed but not linked: 2
- Nierman, 2007, Safety and efficacy of AMT-010, an adeno-associated virus based gene therapy vector administered to lipoprotein lipase-deficient subjects, Hum. Gene Ther., 18, 942
- Mingozzi, 2007, Capsid-specific T cell responses in humans upon intramuscular administration of an AAV-1 vector expressing LPLs447X transgene, Hum. Gene Ther., 18, 94
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“One key concept to keep in mind when studying immune responses to AAV vectors is that the viral capsid is identical or nearly identical to the capsid of the wild-type virus, to which humans are exposed.(4,61,62) Thus, it is expected that the host immune responses”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“The prevalence of T cells directed against AAV1 and AAV2 in the general population has been investigated through a variety of functional assays, which include enzyme-linked immunospot (ELISPOT) and flow cytometry-based assays.(42,45,47) Although the prevalence can vary across studies, depending on the sensitivity of t…”
BackgroundHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“This may explain why different independent studies reported a lack of correlation between preexisting cellular and humoral immune responses (50, 56, 58).”
BackgroundMethodInfluentialPre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
“In most of these studies, there was a significant—but not perfect—correlation between the anti-AAV immunoglobulin titers determined by ELISA and the neutralizing titers (Chirmule et al., 1999; Erles et al., 1999; Murphy et al., 2009; Boutin et al., 2010; Veron et al., 2012).”
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Self-citationHumoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243
“Several studies addressed the prevalence of NAbs to these new serotypes and compared them to previously described serotypes (25, 29, 30, 32, 47).”
ResultBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192
“The use of a dual-assay strategy based on neutralization and binding assays has been proposed to identify subjects seronegative to AAV.41 This is an acceptable approach to patient screening, as NAbs generally correlate to total IgG binding to AAV.42 However, our data indicate that NAb assays should be preferred over t…”
BackgroundSelf-citationKruzik, A., Fetahagic, D., Hartlieb, B., Dorn, S., Koppensteiner, H., Horling, F. M., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.014 · Cited by 182
“Similar observations have been reported for AAV1.(24) Therefore, it could be speculated that anti-AAV T cells are tissue resident(25) or circulating at very low frequencies.”
ResultMartino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis
Le Meur, G., Lebranchu, P., Billaud, F., Adjali, O., Schmitt, S., Bézieau, S., Péréon, Y., Valabregue, R., Ivan, C., Darmon, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.014 · Cited by 137
Self-citationMeliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127
Self-citationSchulz, M., Levy, D. I., Petropoulos, C. J., Bashirians, G., Winburn, I., Mahn, M., Somanathan, S., Cheng, S. H., & Byrne, B. J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.010 · Cited by 125
Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs
Mack, D. L., Poulard, K., Goddard, M. A., Latournerie, V., Snyder, J. M., Grange, R. W., Elverman, M. R., Denard, J., Veron, P., Buscara, L., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.004 · Cited by 114
“MTM1 Protein Cellular immune responses specific to the AAV8 capsid in dogs were monitored by IFN-g enzyme-linked immunospot (ELIspot) assays as previously described.(39)”
MethodSelf-citationHareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“Screening of randomised healthy donors gave insights into immune responses to natural AAV1 infection with no correlation existing between AAV1-specific T-cell and humoral responses [48].”
BackgroundGreenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Pogoda, J. M., Provost, R., Guerrero, J., Hajjar, R. J., & Zsebo, K. M. (2016) · Gene Therapy · doi:10.1038/gt.2015.109 · Cited by 111
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104
“In agreement with previously published observations (22, 26, 40), we found that AAV2 capsid triggered a response in CD8+ T cells (Figure 2B).”
MethodResultInfluentialSelf-citationCapsid-specific removal of circulating antibodies to adeno-associated virus vectors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100
Self-citationAAV Vectors Vaccines Against Infectious Diseases
Nieto, K., & Salvetti, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00005 · Cited by 100
“Epidemiological studies indicate that anti-AAV Ab can be detected in the majority of the population worldwide and that their seroprevalence varies according to the AAV serotype and the geographical region (69) (70) (71) [for a review, see Ref.”
BackgroundCell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
“(82) conducted a similar survey for AAV1 in PBMCs from healthy donors.”
BackgroundUnderstanding AAV vector immunogenicity: from particle to patient
Dhungel, B. P., Winburn, I. C., Pereira, C. D. F., Huang, K., Chhabra, A., & Rasko, J. E. J. (2024) · Theranostics · doi:10.7150/thno.89380 · Cited by 101
“This suggests that patient screening should include testing for pre-existing AAV-specific cellular responses in addition to anti-AAV NAbs [74].”
BackgroundT Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
“Another group using ELISPOT assays as well as ICS showed with either assay that ~30% of health human adults respond to AAV1 capsid (33).”
BackgroundMethodMonahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
“Unmethylated CpG motifs are uncommon in mammalian DNA but common in microbial DNA and may induce innate host defenses.”
BackgroundInfluentialAAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
Hui, D. J., Edmonson, S. C., Podsakoff, G. M., Pien, G. C., Ivanciu, L., Camire, R. M., Ertl, H., Mingozzi, F., High, K. A., & Basner-Tschakarjan, E. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.29 · Cited by 84
Aronson, S. J., Veron, P., Collaud, F., Hubert, A., Delahais, V., Honnet, G., de Knegt, R. J., Junge, N., Baumann, U., Di Giorgio, A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.143 · Cited by 65
Self-citationFuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Boisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Leborgne, C., Latournerie, V., Boutin, S., Desgue, D., Quéré, A., Pignot, E., Collaud, F., Charles, S., Simon Sola, M., Masat, E., et al. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2018.03.004 · Cited by 53
“Alternatively, upon exposure to AAV, some subjects may not develop antibodies to AAV but only T cells reactive to the capsid [49].”
BackgroundSelf-citationHumoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Modeling Graves’ Orbitopathy in Experimental Graves’ Disease
Moshkelgosha, S., Berchner‐Pfannschmidt, U., Eckstein, A., & Banga, J. P. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1555956 · Cited by 55
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
Hui, D. J., Basner-Tschakarjan, E., Chen, Y., Davidson, R. J., Buchlis, G., Yazicioglu, M., Pien, G. C., Finn, J. D., Haurigot, V., Tai, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.166 · Cited by 47
Piguet, F., de Saint Denis, T., Audouard, E., Beccaria, K., André, A., Wurtz, G., Schatz, R., Alves, S., Sevin, C., Zerah, M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.105 · Cited by 45
Regulatory and Exhausted T Cell Responses to AAV Capsid
Gernoux, G., Wilson, J. M., & Mueller, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.022 · Cited by 44
Gernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
“The fact that it was not predicted in animal models can be due to the pre-existing immunity to AAV capsid in humans.(30,52,53) Even if monkeys are natural hosts of AAV, their pre-existing capsid-specific T cells differ from those of humans, with an effector phenotype compared to a memory phenotype in humans, and also…”
BackgroundUnderstanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
“80 IgG-binding titers correlate with NAb titers, 81 and in the context of natural immunity to AAV tend to be low to moderate.”
Differential T cell immune responses to deamidated adeno-associated virus vector
Bing, S. J., Justesen, S. F. L., Wu, W. W., Sajib, A. M., Warrington, S., Baer, A., Thorgrimsen, S., Shen, R., & Mazor, R. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.005 · Cited by 40
Zhao, Z., Kim, J., Suja, V. C., Kapate, N., Gao, Y., Guo, J., Muzykantov, V. R., & Mitragotri, S. (2022) · Advanced Science · doi:10.1002/advs.202201293 · Cited by 36
Gene therapy for mitochondrial disorders
Keshavan, N., Minczuk, M. A., Viscomi, C. F., & Rahman, S. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12699 · Cited by 43
Kassner, U., Hollstein, T., Grenkowitz, T., Wühle-Demuth, M., Salewsky, B., Demuth, I., Dippel, M., & Steinhagen‐Thiessen, E. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.007 · Cited by 38
“23 An early study with ali-pogene tiparvovec did not use immunosuppressants, and all eight patients developed antibodies against AAV-1 capsid epitopes, and four developed a T-cell response against AAV-1.”
Gardner, M. R., Mendes, D. E., Muniz, C. P., Martinez-Navio, J. M., Fuchs, S. P., Gao, G., & Desrosiers, R. C. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.003 · Cited by 30
Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis
Gao, R., Zu, W., Liu, Y., Li, J., Li, Z., Wen, Y., Wang, H., Yuan, J., Cheng, L., Zhang, S., et al. (2021) · Virulence · doi:10.1080/21505594.2021.1911477 · Cited by 33
Denard, J., Marolleau, B., Jenny, C., Rao, T. N., Fehling, H. J., Voit, T., & Svinartchouk, F. (2013) · Journal of Virology · doi:10.1128/jvi.01813-13 · Cited by 31
“Humoral blood factors such as antibodies (20, 33, 34) or complement (35) are the first barriers met by the vectors administered systemically.”
BackgroundTseng, Y.-S., Vliet, K. V., Rao, L., McKenna, R., Byrne, B. J., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virological Methods · doi:10.1016/j.jviromet.2016.07.009 · Cited by 28
“Neutralization assay The neutralization abilities of the newly generated anti-AAV8 and anti-AAV9 antibodies were assayed in HeLa cells (Veron et al. 2012).”
MethodPeeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
Carpentier, M., Lorain, S., Chappert, P., Lalfer, M., Hardet, R., Urbain, D., Peccate, C., Adriouch, S., Garcia, L., Davoust, J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.235 · Cited by 25
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“AAV1 does not naturally infect human cells, so the implications of this observation in broader AAV infections and gene therapy response in humans remain an area for future study.”
BackgroundInfluentialPabinger, I., Ayash‐Rashkovsky, M., Escobar, M. A., Konkle, B. A., Mingot‐Castellano, M. E., Mullins, E. S., Négrier, C., Pan, L., Rajavel, K. S., Yan, B., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00441-5 · Cited by 31
Vandamme, C., Xicluna, R., Hesnard, L., Devaux, M., Jaulin, N., Guilbaud, M., Le Duff, J., Couzinié, C., Moullier, P., Saulquin, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03110 · Cited by 23
“These observations parallel the results already reported for AAV1 (18) and AAV2 (10).”
BackgroundResultSelf-citationKavita, U., Dai, Y., Salvador, L., Miller, W., Adam, L. P., Levesque, P. C., Zhang, Y. J., Ji, Q. C., & Pillutla, R. C. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.131 · Cited by 23
Bartolo, L., Li Chung Tong, S., Chappert, P., Urbain, D., Collaud, F., Colella, P., Richard, I., Ronzitti, G., Demengeot, J., Gross, D. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127008 · Cited by 23
“types, prevalent mostly in humans (5, 6), can impair treatment effectiveness (7), which advocates for the use of other rAAV serotypes, engineered capsids (8), and immunosuppression procedures (9).”
BackgroundMonahan, P. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.33 · Cited by 24
Characterization of Naturally-Occurring Humoral Immunity to AAV in Sheep
Tellez, J., Van Vliet, K., Tseng, Y.-S., Finn, J. D., Tschernia, N., Almeida-Porada, G., Arruda, V. R., Agbandje-McKenna, M., & Porada, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075142 · Cited by 18
Advances in viral vector-based delivery systems for gene therapy: a comprehensive review
Singh, K., Jain, D., Sethi, P., Gupta, J. K., Dubey, A., Noman, A. A., lal, S., Sharma, P., & Abdallah, E. M. (2025) · 3 Biotech · doi:10.1007/s13205-025-04366-7 · Cited by 24
“However, previous studies have shown that AAV vectors have a limited capacity for integration into the genome of animal models (Bella et al. 2020; Nault et al. 2015, 2016; Veron et al. 2012; Chandler et al. 2015; Donsante et al. 2007).”
Ortved, K. F., Wagner, B., Calcedo, R., Wilson, J. M., Schaefer, D. M. W., & Nixon, A. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.050 · Cited by 19
Stolte, B., Schreiber-Katz, O., Günther, R., Wurster, C. D., Petri, S., Osmanovic, A., Freigang, M., Uzelac, Z., Leo, M., von Velsen, O., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.054 · Cited by 15
Therapies for Mitochondrial Disease: Past, Present, and Future
Ball, M., Bergen, N. J. V., Compton, A. G., Thorburn, D. R., Rahman, S., & Christodoulou, J. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70065 · Cited by 24
“Immune response to AAV vector-based gene therapy, usually in the context of neutralising antibodies, can result in some individuals having a reduced response to treatment [206, 207].”
Xicluna, R., Schwalie, P. C., Bell, E., von Tell, D., Steiner, G., Seeger, E., Heeren, J. J. F., Turksma, A. W., Pouw, R. B., Schwandt, T., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101551 · Cited by 16
“12 The last few years have seen a growing interest in understanding the innate immune response to rAAV.”
Sierra-Delgado, J. A., Likhite, S. B., Bautista‐Niño, P. K., Gómez‐Ochoa, S. A., Echeverría, L. E., Guío, E., Vargas, C. I., Serrano, N. C., Meyer, K., & Rincón, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065579 · Cited by 13
Hahn, P. A., & Martins, M. A. (2023) · Journal of Virus Eradication · doi:10.1016/j.jve.2023.100316 · Cited by 15
Xicluna, R., Avenel, A., Vandamme, C., Devaux, M., Jaulin, N., Couzinié, C., Duff, J. L., Charrier, A., Guilbaud, M., Adjali, O., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.225 · Cited by 14
“11,12 As expected, we also report a cellular immune response cross-reactivity between serotypes.”
Simmons, E. M., Wen, Y., Li, J., Qian, Y., Wong, L. C., Konrad, R. J., & Bivi, N. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113397 · Cited by 11
Yang, C., Hao, F., He, J., Lu, T., Klein, R., Zhao, L.-R., & Duan, W.-M. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.083 · Cited by 12
“–43 For example, depletion of CD4 T-lymphocytes or immunosuppression enables successful transgene expression after re-administration of AAV vectors.”
Yang, C., Yang, W.-H., Chen, S.-S., Ma, B.-F., Li, B., Lu, T., Qu, T., Klein, R., Zhao, L.-R., & Duan, W.-M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063876 · Cited by 10
“and to present AAV capsid-specific T cells [15].”
BackgroundAdachi, K., Dissen, G. A., Lomniczi, A., Xie, Q., Ojeda, S. R., & Nakai, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-66596-4 · Cited by 10
Li, X., He, S., Thomas, J., Wu, B., Yang, T., & Swanson, M. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00861-y · Cited by 9
“…therapy clinical studies, no striking correlation was found between pre-existing cellular immunogenicity and pre-existing humoral immunogenicity towards various adeno-associated virus (AAV) serotypes, despite clear evidence of T-cell dependent IgG1 B-cell class switch in 99% of individuals (6,7).”
BackgroundPreclinical Models of Graves’ Disease and Associated Secondary Complications
Moshkelgosha, S., So, P., Díaz‐Cano, S. J., & Banga, J. P. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150316121945 · Cited by 10
“Nevertheless, there are drawbacks of the adenovirus hTSHR A-subunit model of GD, where the viral coat proteins are exceptionally immunogenic leading to a large non-specific immune response to the virus [68].”
BackgroundGene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 7
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Holtkamp, S., Lagoda, F. R., Lister, A., Harish, P., Kleymann, U., Pesch, T., Soon, C. F., Pirmohamed, M., Naisbitt, D. J., & Trautwein, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450524 · Cited by 3
Challenges in Humoral Immune Response to Adeno-Associated Viruses Determination
Naumova, D. A., Krokunova, T., Maksimov, D. O., Mityaeva, O. N., Astakhova, E. A., & Volchkov, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020816 · Cited by 3
“Although some studies show that binding and neutralizing AAV-specific IgGs correlate well [11], measuring NAbs is thought to be more desirable.”
Immune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
Vectrology of adeno-associated viruses (AAV).
Skubis-Zegadło, J., Stachurska, A., & Małecki, M. (2013) · PubMed · Cited by 20
Davis, A. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Laing, N. G. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727345882.793553473
Conboy, I. M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733450908.793553930
Balasubramanian, A., Prachař, M., Klaproth, B., Copeland, V., Justesen, S. F. L., Wen, Y., Siegel, R. W., & Malherbe, L. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1641289 · Cited by 2
Alvisi, M., Roberts, L., Roessig, L., Balderson, D. E., Sanganalmath, S. K., Braun, M., Gordon, S. N., Lacey, S. F., Pandya, P., & Hajjar, R. J. (2026) · Human Gene Therapy · doi:10.1177/10430342261430244 · Cited by 2
“43 While cellular immunity is an important component of the immune response, it represents a broad and complex research area.”
Characterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Bartolo, L. (2018) · theses.fr (ABES) · doi:10.70675/b32b9711za15dz4740z8481z0ba7dd36e8ee
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
MADCAP: isolation of novel nAb-naïve AAV capsids from metagenomic data
Lyashenko, E., Torregrosa, T., Ysasi, A. B., Wu, J. T., Bu, J., Hennessy, M., Na, Y., Ryan, M. J., Takar, M., Manek, R., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00630-26 · Cited by 1
Sánchez-Gutierrez, C., Bohorquez-Zambrano, L. F., Garnica-Álvarez, C., Rincón, M. Y., & Valderrama‐Aguirre, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1925844 · Cited by 1
Metadata
- Authors
- Veron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C.
- Affiliations
- Genethon (France) (FR)
- Inserm (FR)
- Corresponding author
- Veron, Philippe
- Leborgne, Christian
- Monteilhet, Virginie
- Boutin, Sylvie
- Moullier, Philippe
- Masurier, Carole
- ORCID
- Leborgne, Christian
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06
- Volume
- 188
- Issue
- 12
- Pages
- 6418-6424
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2170549121
- Cited by
- 88
- References
- 30
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 6 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 10 · 2017: 9 · 2016: 4 · 2015: 8 · 2014: 3 · 2013: 9 · 2012: 1
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus type 1, humoral immune response, neutralizing antibodies, CD8+ effector memory T cells, CD4+ T cells, interferon-gamma, AAV serotypes, gene therapy safety, healthy donors
- MeSH terms
- Dependovirus, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Genetic Vectors, Humans, Immunity, Cellular, Immunologic Memory, Random Allocation, T-Lymphocytes, Genetic Therapy, Capsid Proteins, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.